Drugs / SIM0811
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07345364 | Jan → Jul 2026 overdue | — | Jiangsu Simcere Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-02-03 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Novel Anti-Stroke Candidate SIM0811 Doses First Participant in Phase I Clinical Trial simcere.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SIM0811 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07345364 ↗ |
| Route | Intravenous | “intravenous bolus plus infusion administration” NCT07345364 ↗ |